Steps Toward
Healing
1) Evaluation and eligibility review
Secure medical record review (pathology, imaging, treatment history), Lab screening (organ function, infection screening), Risk assessment and a treatment plan discussion. This is also where clinicians compare options such as Targeted Therapy, checkpoint Immunotherapy, transplant, CAR-T Therapy, and supportive care.
2) Program confirmation and coordination
Trial vs hospital program pathway, Cell source confirmed (patient vs donor), Pre-treatment planning (some patients require “bridging” therapy to control disease while the program is arranged)
3) Cell manufacturing / preparation (protocol-dependent)
Collection (apheresis) if patient-derived Processing under controlled quality systems with release testing and chain-of-identity documentation (requirements vary by hospital program), Logistics coordination for the infusion schedule. Beijing Biotech can support documentation and coordination steps aligned to the hospital’s protocol.
4) Infusion
Cells are administered (most commonly IV) Immediate monitoring for fever, blood pressure changes, breathing symptoms, or allergic-type reactions
5) Monitoring and early follow-up
Close observation (inpatient or outpatient, depending on risk and hospital protocol), Labs and clinical checks to detect early immune toxicities and infection risk
6) Longer-term follow-up
Response assessment (disease-specific: imaging, bone marrow tests, blood markers), Ongoing follow-up plan – including coordination with your home oncology team when you return abroad
Conditions we commonly support
Patients most often inquire about NK/CAR-NK for:
- Leukemia (e.g., ALL, AML – program-dependent)
- Lymphoma (e.g., certain B-cell non-Hodgkin lymphomas – program-dependent)
- Other hematologic cancers may be considered case-by-case depending on the hospital protocol.
Solid tumors (important context): For many solid tumors, NK or CAR-NK approaches are investigational and commonly limited to clinical trials or carefully defined hospital research protocols. A treating oncologist must confirm whether a program exists for your tumor type and whether it is appropriate.
FAQ
1.Is NK Cell Therapy available in China for international patients?
NK Cell Therapy may be available in China through hospital programs and/or registered clinical trials, depending on the diagnosis and the treating center’s capabilities. Availability varies by hospital, city, and protocol. Medical disclaimer: This is not medical advice; eligibility must be confirmed by a licensed physician.
2.Is CAR-NK therapy offered in Beijing, Shanghai, or Guangzhou?
Some hospitals and research programs in major hubs like Beijing, Shanghai, and Guangzhou may offer CAR-NK within specific protocols or trials. Program access depends on the cancer type (often Leukemia/Lymphoma) and trial criteria.
3.CAR-NK vs CAR-T Therapy: which one is safer?
Both require specialized monitoring. CAR-T has well-characterized risks such as cytokine release syndrome (CRS) and neurotoxicity (ICANS). CAR-NK is being studied with potentially different toxicity patterns in some reports, but side effects can still occur. The safest choice is the option a qualified center can deliver with strong monitoring and emergency pathways.
4.What cancers are most commonly considered for NK or CAR-NK therapy?
Most patient inquiries focus on hematologic cancers – especially Leukemia and Lymphoma – because many programs and trials target these diseases. Solid tumor use is often investigational and depends on trial availability.
5.What is the Cost / Price of CAR-NK therapy in China?
Costs vary widely and depend on trial vs hospital pathway, cell source (patient vs donor), engineering complexity, manufacturing/testing requirements, monitoring intensity, supportive care, and the hospital/city fee structure. A responsible estimate requires medical review and an itemized quote.
6.Can you share the CAR-NK success rate in China?
A single universal Success Rate is not appropriate because outcomes vary by diagnosis subtype, prior treatments, protocol design, and follow-up duration. Ask for peer-reviewed or trial-based outcomes that match your exact disease and clinical situation. No provider can ethically guarantee outcomes for an individual.
7.How long does the NK/CAR-NK process usually take (timeline)?
Timelines depend on evaluation speed, trial enrollment steps, cell sourcing, manufacturing, and scheduling. Some patient-derived processes can take longer, while some donor-based protocols may be faster (program-dependent). A hospital team can provide a realistic schedule after reviewing records.
8.What side effects should families watch for after infusion?
Hospitals monitor for infusion reactions, fever, blood pressure changes, breathing symptoms, CRS, neurologic symptoms, infection risk, and lab abnormalities. Patients should follow the hospital’s discharge instructions and report symptoms immediately.
9.Do I need to travel to China for the first evaluation?
Often, an initial screening can start remotely with medical records. Many programs still require an in-person assessment before treatment to confirm eligibility, labs, and safety planning.
10.How do I choose the best hospital for NK/CAR-NK therapy in China?
Use objective criteria: experience with your diagnosis, trial access, dedicated cell therapy team, ICU readiness, clear adverse event protocols, transparent documentation (release testing, chain-of-identity), and a defined follow-up plan – especially for international return-home care.
11.Can NK/CAR-NK be combined with Proton Therapy, Targeted Therapy, or Immunotherapy?
Sometimes therapies are sequenced or coordinated, but combinations are not automatic and depend on safety and evidence for your case. Decisions must be made by a multidisciplinary oncology team.
12.What medical records do you need for an eligibility review?
Typically: pathology/diagnosis reports, recent imaging (CT/PET/MRI), treatment history (including Targeted Therapy and Immunotherapy), recent labs, and a physician summary if available. Missing records can delay or prevent accurate eligibility screening.